November 10, 2020
[Moscow – 10.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new access mode to Immune Response Template (IRT) version 3. Now any modeler can experience or get acquainted with IRT via Demo access without the necessity to purchase the license.
Generally, IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been expanded to a fully-fledged database that embraces a wide range of reactions and species. However, InSysBio constantly goes further in its software advancement.
Demo access to IRT version 3 provides the opportunity to fully utilize 5 schemes, 2 cell passports, 2 cytokine passports and 1 immunologic synapse: IDEC, Th17, CCL20, IL17, Th0:IDECa. All the functionality of IRT Navigator is also available within the Demo version.
The instruction to get demo access to IRT version 3:
*If you don’t have an account yet:
About Immune Response Template (IRT):
IRT is a Quantitative Systems Pharmacology (QSP) platform of immune system and tool for development of QSP and mechanistic models related to immune response.
IRT consist of IRT Database and IRT Navigator. The core of IRT Database is IRT Core Model, a QSP model of immune system. IRT Navigator is an application software providing intuitive interface to work with IRT Database. IRT is an innovative tool allowing users to select all or any reactions and species from IRT Core Model and download it. To get more information please, visit: irt.insysbio.com
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
← | October 2022 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
| |||||
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
1.
12 Oct 2022 16:07
InSysBio to take part in ACoP13
InSysBio announces its participation in the Thirteenth American Conference on Pharmacometrics (ACoP13) which is to be held in person from October 30th to November 2nd, 2022, at the Gaylord Rockies Resort & Convention Center in Aurora, Colorado. InSysBio team is going to present 7 posters in frames of the Conference
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
1.
25 Oct 2022 14:41
InSysBio to present its ePoster at ECTRIMS 2022
InSysBio team is going to present its poster in frames of 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis which is to be held October 26-28, Amsterdam, the Netherlands. The ePoster is going to be presented in frames of "Pathology and pathogenesis of MS - Neurodegeneration" ePoster Area, October 26
|
26
|
27
|
28
|
29
|
30
|
31
|